Calidi Biotherapeutics ( (CLDI) ) has shared an announcement.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Calidi Biotherapeutics, a biotechnology company specializing in targeted antitumor therapies, has been notified by the NYSE that its warrants, trading under CLDI WS, will be delisted due to low trading prices. However, trading of Calidi’s common stock, CLDI, remains unaffected. The company is exploring options to appeal the decision. Calidi continues its focus on developing innovative cancer treatments through its stem cell-based platforms.
Find detailed analytics on CLDI stock on TipRanks’ Stock Analysis page.
